Twist Bioscience Corporation (TWST)

NMS – Real vaqt narxi. Valyuta: USD

125.21

+2.09 (1.70%)

Yopilishda: Aug 12, 2026, 4:00 PM EDT

123.81

-1.40 (-1.12%)

Bozordan keyin: Aug 12, 2026, 5:11 PM EDT

06.08.2026

Artisan Global Discovery Fund Q2 2026 Portfolio Activity

During the quarter, we initiated new positions in Entegris, Cellebrite and C.H. Robinson. In addition to Lattice Semiconductor and Babcock, we added to Games Workshop Group, Tradeweb Markets and Teledyne Technologies during the quarter. In addition to ROBLOX, we ended our investment campaigns in Colliers International and MongoDB.

05.08.2026

Twist Biosciences: Accelerating Growth, Diminishing Margin Of Safety

Twist Bioscience's stock has surged in 2026 on the back of improved growth and growing optimism about the AI-enabled drug discovery opportunity. Growth will be driven by triple-digit AI-enabled drug discovery order growth, and oncology diagnostic assay commercialization. Operating leverage, manufacturing improvements, and the introduction of higher value-add products will also see Twist's margins continue to improve.

05.08.2026

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten public offering of 3,125,000 shares of its common stock at a price to the public of $96.00 per share. All of the shares of common stock to be sold in the public offering are to be sold by Twist. The gross proceeds to Twist from the offering, before deducting the underwriting discounts and commissio.

04.08.2026

Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock. In addition, Twist intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock. All of the shares of common stock to be sold in the proposed offering are being offered by.

04.08.2026

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 44,434 restricted stock units (“RSUs”) will be granted to 24 recently hired individuals, in each case as an inducement material to their acceptance of employment with Twist. The employment inducement awards will be granted under Twist's Amended and Res.

03.08.2026

Twist Bioscience Corporation (TWST) Q3 2026 Earnings Call Transcript

03.08.2026

Twist Bioscience Sees AI Drug Discovery Pipeline Expand

Twist Bioscience Corporation (NASDAQ:TWST) stock is up on Monday as the company reported its fiscal 2026 third-quarter financial results and raised fiscal 2026 guidance.

Videolar

No Data

There is no data to display

Press-relizlar

05.08.2026

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

04.08.2026

Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock

04.08.2026

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

03.08.2026

Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the third quarter fiscal 2026 ended June 30, 2026. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal third quarter 2026 earnings report and the investor presentation, or click https://investors.twist.

Twist Bioscience Corporation (TWST)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Twist Bioscience Corporation (TWST)

Artisan Global Discovery Fund Q2 2026 Portfolio Activity

Twist Biosciences: Accelerating Growth, Diminishing Margin Of Safety

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience Corporation (TWST) Q3 2026 Earnings Call Transcript

Twist Bioscience Sees AI Drug Discovery Pipeline Expand

Videolar

No Data

Press-relizlar

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results

Artisan Global Discovery Fund Q2 2026 Portfolio Activity

Twist Biosciences: Accelerating Growth, Diminishing Margin Of Safety

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience Corporation (TWST) Q3 2026 Earnings Call Transcript

Twist Bioscience Sees AI Drug Discovery Pipeline Expand

Videolar

No Data

Press-relizlar

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results

Search stocks

Twist Bioscience Corporation (TWST)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Twist Bioscience Corporation (TWST)

Artisan Global Discovery Fund Q2 2026 Portfolio Activity

Twist Biosciences: Accelerating Growth, Diminishing Margin Of Safety

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience Corporation (TWST) Q3 2026 Earnings Call Transcript

Twist Bioscience Sees AI Drug Discovery Pipeline Expand

Videolar

No Data

Press-relizlar

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results

Artisan Global Discovery Fund Q2 2026 Portfolio Activity

Twist Biosciences: Accelerating Growth, Diminishing Margin Of Safety

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience Corporation (TWST) Q3 2026 Earnings Call Transcript

Twist Bioscience Sees AI Drug Discovery Pipeline Expand

Videolar

No Data

Press-relizlar

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results